Dr. Frey on Measuring MRD Throughout Treatment for ALL

Video

Noelle Frey, MD, MSCE, discusses measuring minimal residual disease throughout treatment for patients with acute lymphocytic leukemia.

Noelle Frey, MD, MSCE, associate professor of medicine, Perelman School of Medicine, University of Pennsylvania, discusses measuring minimal residual disease (MRD) throughout treatment for patients with acute lymphocytic leukemia (ALL).

Measuring MRD throughout treatment should be a standard of care for all patients with ALL because MRD helps the patient and physician understand the disease prognosis, explains Frey. When patients are MRD positive, even when they are in complete remission, their chances of relapsing are very high, says Frey.

Newer agents that work very differently than chemotherapy are important tools for patients who are MRD positive and resistant to chemotherapy, according to Frey. Blinatumomab (Blincyto), which was approved by the FDA in March 2018 to treat patients with ALL who are MRD positive, Frey concludes.

Related Videos
Emmanuel Antonarakis, MD, associate director, Translational Research, Masonic Cancer Center, University of Minnesota, Clark Endowed Professor of Medicine, University of Minnesota Medical School
Gautam Jha, MD, medical director, M Health Fairview Masonic Cancer Clinic and the Advanced Treatment Center at the M Health Fairview Clinics and Surgery Center—Minneapolis, chair, cancer committee, M Health Fairview Ridges Hospital
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute